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Background: Understanding how inflammation causes neuronal damage is of paramount importance in multiple
sclerosis (MS) and in other neurodegenerative diseases. Here we addressed the role of the apoptotic cascade in the
synaptic abnormalities and neuronal loss caused by the proinflammatory cytokines interleukin-1β (IL-1β) and tumor
necrosis factor (TNF-α) in brain tissues, and disease progression caused by inflammation in relapsing-remitting MS
(RRMS) patients.
Results: The effect of IL-1β, but not of TNF-α, on glutamate-mediated excitatory postsynaptic currents was blocked
by pifithrin-α (PFT), inhibitor of p53. The protein kinase C (PKC)/transient receptor potential vanilloid 1 (TRPV1)
pathway was involved in IL-1β-p53 interaction at glutamatergic synapses, as pharmacological modulation of this
inflammation-relevant molecular pathway affected PFT effects on the synaptic action of IL-1β. IL-1β-induced neuronal
swelling was also blocked by PFT, and IL-1β increased the expression of p21, a canonical downstream target of
activated p53.
Consistent with these in vitro results, the Pro/Pro genotype of p53, associated with low efficiency of transcription
of p53-regulated genes, abrogated the association between IL-1β cerebrospinal fluid (CSF) levels and disability
progression in RRMS patients. The interaction between p53 and CSF IL-1β was also evaluated at the optical
coherence tomography (OCT), showing that IL-1β-driven neurodegenerative damage, causing alterations of
macular volume and of retinal nerve fibre layer thickness, was modulated by the p53 genotype.
Conclusions: Inflammatory synaptopathy and neurodegeneration caused by IL-1β in RRMS patients involve the
apoptotic cascade. Targeting IL-1β-p53 interaction might result in significant neuroprotection in MS.
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The immune and central nervous systems are more in-
timately related than previously supposed. Effector im-
mune cells are regulated by neurotransmitters [1-3], and
cytokine signaling in the brain is known to modulate im-
portant functions, including neurotransmitter metabol-
ism, neuroendocrine function, synaptic plasticity, as well* Correspondence: centonze@uniroma2.it
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unless otherwise stated.as the neural circuitry of cognition and mood [4-10]. On
the other hand, this link may be the condition for patho-
logical processes. Neuroinflammation is a hallmark of
most neurological diseases, such as multiple sclerosis
(MS) and other neurodegenerative diseases [11,12].
Proinflammatory cytokines, such as tumor necrosis
factor (TNF-α) and interleukin-1β (IL-1β), have been
shown to increase synaptic transmission and to induce
excitotoxic neuronal damage [4,7,13-15]. Furthermore,
we have recently demonstrated that IL-1β plays a role in
MS-associated neurodegenerative damage and clinical
progression [16]. However the molecular mechanisms ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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unclear.
Aim of our work was to investigate the possible role
of the apoptotic cascade in the inflammatory neurode-
generation in vitro and in MS patients. Proinflamma-
tory cytokines are able to induce p53, and are involved
in the enhancement of p53-mediated apoptosis [17-22].
In neurons, the tumor-suppressor protein p53 is be-
lieved to play roles in physiological apoptosis, as well as
in the neuronal death that occurs in disorders such as
Parkinson’s disease, Alzheimer’s disease, and stroke
[23-27]. Notably, the gene encoding p53 (TP53 gene)
presents a common single nucleotide polymorphism
(SNP; G-to-C transversion) at codon 72 (rs1042522).
The two resulting variants (Arg and Pro) are not func-
tionally equivalent, either biochemically or biologically,
with the p53Arg variant being more efficient than the
p53Pro to induce apoptosis [28-31].
Investigating how p53 genetic variants influence the
synaptic and toxic effects of proinflammatory cytokines
might provide further crucial insights into the patho-
physiology of the neurodegenerative damage of MS
and, possibly, of other neurological diseases.
Results
p53 regulates the effects of IL-1β at glutamatergic
synapses
Both IL-1β and TNF-α modulate glutamate-mediated trans-
mission at central synapses [4,7]. Here, the role of p53 in IL-
1β- and TNF-α-mediated synaptic effects were investigated.
As reported [7], IL-1β enhanced the frequency of glutamate-
mediated spontaneous excitatory post-synaptic currents
(sEPSCs) in mouse corticostriatal brain slices (n = 11, p <
0.05 respect to pre-drug values), an effect that was prevented
by IL1ra (n = 8, p > 0.05 respect to pre-drug values). We then
explored, for the first time, the synaptic effects of IL-1β-p53
interaction. We found that IL-1β failed to enhance sEPSCs
in slices incubated with the p53 inhibitor PFT (n = 17, p >
0.05 respect to pre-drug values), indicating the crucial role
of p53 in the IL-1β synaptic effects (Figure 1A).
Conversely, the effect of TNF-α on glutamatergic trans-
mission was not mediated by p53. TNF-α, in line with our
previous report [4], caused the expected enhancement of
sEPSC decay time and half-width in corticostriatal brain
slices (n = 11, p < 0.05 respect to control), and here we
showed that this effect was still present in PFT-treated
slices (n = 17, p < 0.05 respect to control, p > 0.05 respect
to TNF-α alone) (Figure 1B). The effect of p53 modulation
on TNF-α synaptic effect was never assessed before.
Involvement of PKC/TRPV1 pathway in IL-1β-p53
interaction at glutamatergic synapses
IL-1β effects on sEPSC are lost after genetic or pharma-
cological inhibition of TRPV1 channels [7]. The possiblerole of these channels in the IL-1β-p53 interaction was
therefore investigated. Capsaicin, agonist of TRPV1
channels, caused a rapid and transient increase of sEPSC
frequency in control conditions (n = 13, p < 0.05), but
not in slices pre-treated with PFT (n = 17, p > 0.05), indi-
cating that p53 is fundamental for TRPV1 channel syn-
aptic effects (Figure 2A). IL-1β stimulates PKC at
glutamatergic nerve terminals [7], and PKC is a major
activator of TRPV1 channels [32]. PKC activation with
phorbol 12-myristate 13-acetate (PMA) was able to
mimic IL-1β effects on sEPSC frequency in control
slices (n = 15, p < 0.05) but not in the presence of PFT
(n = 14, p > 0.05), confirming the relevance of PKC/
TRPV1 pathway in IL-1β-p53 interaction at glutamatergic
synapses (Figure 2B). In line with this, the p53 activator
nutlin-3 enhanced the increase of sEPSC frequency medi-
ated by IL-1β (n = 12, p < 0.05), but not in the presence of
the TRPV1 antagonist capsazepine (n = 10, p > 0.05) or
of the PKC inhibitor chelerythrine (n = 10, p > 0.05)
(Figure 2C).
p53 regulates the in vitro neurotoxic effect of IL-1β
Abnormal glutamate transmission causes excitotoxic
damage that can be studied in brain slices by measuring
neuronal swelling, which reflects the disruption of
membrane selective permeability to ions and water [7].
Time-dependent cell swelling was significantly more pro-
nounced in slices incubated with IL-1β (n = 7) than in
control conditions (n = 5; p < 0.05). PFT or cyano-nitroqui-
noxaline-dione (CNQX) attenuated cell swelling in slices
treated with IL-1β (n = 10 for both experiments; p < 0.05),
confirming that this proinflammatory cytokine causes
neuronal damage through an excitotoxic mechanism
regulated by p53 (Figure 3A, B).
IL-1β activates p53 pathway
p53 might play only a permissive role in IL-1β effects or
could be activated by IL-1β, thus enhancing synaptic
function. In order to evaluate whether IL-1β activates
p53 pathway, we analysed the content of p21, which rep-
resents a canonical downstream target of activated p53
[33]. We found that IL-1β significantly increases the
expression of p21 protein indicating that activation of
p53 pathway occurs after IL-1β incubation (Figure 3C).
Of note, the levels of p53 were not detectable in our
samples probably due to the continuous proteasome-
dependent degradation of p53, as already reported [34].
Interaction between p53 and IL-1β clinical effects in MS
patients
Since p53-dependent apoptosis plays a role in neuronal
damage of neurodegenerative diseases [23-27], and can
be induced by inflammatory cytokines [17-22], we in-
vestigated if a SNP of TP53 gene, known to alter the
Figure 1 Role of p53-IL-1β interaction on glutamate synaptic transmission. A. The graph shows that application of IL-1β, in mice brain slices,
significantly enhanced sEPSC frequency (p < 0.05 respect to pre-drug values), an effect fully prevented by both IL-1ra and the p53 inhibitor PFT
(p < 0.05 respect to pre-drug values). The electrophysiological traces on the right are examples of sEPSCs recorded from single striatal neurons,
before and during the application of IL-1β, in control conditions and in slices pre-treated with PFT. B. PFT failed to affect TNF-α effects on sEPSC
duration (p > 0.05). The electrophysiological traces on the right are examples of sEPSC mean peak, obtained by group analysis and
recorded from striatal neurons in the presence of TNF-α and PFT. *means p < 0.05.
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toxic effect of IL-1β in relapsing-remitting MS (RRMS)
patients. We have recently demonstrated that the CSF
detection of IL-1β in phase of remission predicts disease
progression in MS [16]. Comparing between patients
with undetectable and detectable CSF levels of IL-1β at
baseline, we found that mean Progression Index (PI)
and MS Severity Scale (MSSS) were significantly lower
among subjects with undetectable IL-1β (PI: 0.19 ± 0.1
versus 0.29 ± 0.2; MSSS: 2.26 ± 2.1 versus 3.41 ± 2.6, p <
0.01 for both parameters).
Then, we grouped patients with detectable levels of
IL-1β according to the p53 codon 72 (Arg72Pro) poly-
morphism, following the dominant and recessive
models (Table 1). The analysis of variance showed sig-
nificant p53 genotype–IL-1β interaction effects on PI
and MSSS (Table 2). The Pro/Pro IL-1β + subjects
showed lower levels of both PI and MSSS with respect
to Arg/Arg and Arg/Pro carriers (PI: 0.09 ± 0.1 versus
0.33 ± 0.19 versus 0.30 ± 0.20; MSSS: 0.91 ± 0.88 versus
4.26 ± 2.58 versus 3.28 ± 2.58), indicating slower disabil-
ity progression despite exposure to IL-1β. Significant
interaction effect for the recessive genetic models was
also found, whereas no interaction effect for the domin-
ant model was present (Table 2).Interaction between p53 and IL-1β neurotoxic effects in
MS patients
The analysis of covariance, adjusted for disease duration,
showed significant p53 genotype–IL-1β interaction effects
on macular volume (MV) and retinal nerve fibre layer
(RNFL) thickness, indicating that also neuronal damage in
IL-1β + group was modulated by the Pro/Pro genotype.
The analysis of covariance for the recessive models
highlighted a significant interaction effect with IL-1β on
MV and RNFL thickness (Table 2). Pro/Pro IL-1β + sub-
jects showed higher levels of MV and RNFL thickness with
respect to Arg/Arg and Arg/Pro carriers (MV: 7.35 ± 0.87
versus 6.42 ± 0.76 versus 6.86 ± 0.56; RNFL: 107.53 ± 12.9
versus 93.38 ± 9.07 versus 100.09 ± 7.2), indicating better
neuronal preservation despite the exposure to IL-1β. Al-
though our sample was too small to test other statistical
associations, higher values of both PI and MSSS were
present in Arg/Arg carriers among patients with undetect-
able IL-1β (PI: Pro/Pro 0.16 +/− 0.13, Arg/Pro 0.14 +/−
0.09, Arg/Arg 0.21 +/− 0.17; MSSS: Pro/Pro 1.73 +/− 1.62,
Arg/Pro 1.73 +/− 1.68, Arg/Arg 2.61 +/− 2.33).
Discussion
Neuroinflammation in MS induces demyelination by
lymphocyte/macrophage infiltration, microglial/astrocytic
Figure 2 Role of PKC/TRPV1 pathway in IL-1β-p53 interaction on
glutamate synaptic transmission. A. Capsaicin, agonist of TRPV1
channels, caused a rapid and transient increase of sEPSC frequency in
control conditions (p < 0.05) but not in slices pre-treated with PFT
(p > 0.05). B. PKC activation with PMA was able to mimic IL-1β effects
on sEPSC frequency in control slices, but not in presence of PFT.
C. Nutlin, a p53 activator, enhances the IL-1β effects on sEPSC
frequency (p < 0.05 respect to pre-drug value), but not in the presence
of capsazepine (p > 0.05), TRPV1 channels antagonist, or chelerythrine
(p > 0.05), PKC antagonist.
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rodegeneration independently accompanies inflammation
since the early stages of MS, and involves not only overtlydemyelinated areas, but also normal appearing white and
grey matter [36,37]. Noteworthy, in addition to focal axon
damage induced by demyelination, neuronal damage
seems also an early and independent event, directly trig-
gered by glutamate and cytokine exposure [14,38-40].
Aim of this study was to assess the role of p53 in the
synaptic and neurotoxic effects of IL-1β and of TNF-α in
patients with MS. Both inflammatory cytokines enhance
glutamate transmission [4,7,41], and excessive glutamater-
gic signaling is detrimental for neuronal survival, through
a process termed excitotoxicity [42,43]. Here we found
that IL-1β-, but not TNF-α-mediated synaptic and neuro-
toxic effects were mediated by p53, since its pharmaco-
logical inhibition prevented sEPSC frequency alteration
and cell swelling caused by IL-1β in vitro. Neuronal swell-
ing directly reflects changes in ion omeostasis and disrup-
tion of neuronal membrane potential [44], suggesting that
the neurotoxic effects of IL-1β is a primary event, even in-
dependently of myelin damage. We found that IL-1β sig-
nificantly increased the expression of p21 protein, which
represents a canonical downstream target of activated p53
[33], indicating that activation of p53 pathway occurs after
IL-1β exposure in the mouse brain. Furthermore, we iden-
tified TRPV1 channels as critical molecular targets of the
action of p53 at glutamatergic synapses. TRPV1 channels
are non-selective cation channels initially recognized to be
activated by capsaicin, the pungent component of hot
peppers [45], high temperature or low pH [46]. Early
studies have supported a main pro-inflammatory role of
TRPV1 channels, because mice lacking these channels
show a reduction of pro-inflammatory cytokine release,
and a decrease of inflammation-driven tissue damage
[47-49]. We have previously demonstrated that these
channels are essential mediators of the cellular effects
of IL-1β [7], but, to our knowledge, this is the first evi-
dence for a role in the synaptic effects of p53.
We also provided evidence for the involvement of
PKC/TRPV1 pathway in the IL-1β-p53 interaction at
glutamatergic synapses. In the presence of the TRPV1
antagonist capsazepine or of the PKC inhibitor cheler-
ythrine, in fact, the action of p53 activator nutlin-3 on
IL-1β synaptic effects was lost. Nutlins were identified as
the first potent and specific small molecule Mdm2 antago-
nists that inhibit the p53-Mdm2 interaction, thus select-
ively increasing p53 levels and inducing apoptosis [50].
Nutlin-3 has been shown to limit the cellular effects of
other inflammatory cytokines, like TNF-α, in neoplastic
cells [51], but no previous evidence exists about the
modulation of the IL-1β effects in neurons. Of note, IL-1β
concentration used for in vitro experiments was in the
range of ng/ml, but we have previously demonstrated that
IL-1β CSF levels, although at lower concentration, are
associated to functional changes of cortical excitability
among MS patients [7].
Figure 3 Role of p53-IL-1β interaction on neuronal damage. A. The graphs show that time-dependent cell swelling was significantly more
pronounced in slices incubated with IL-1β than in control conditions (p < 0.05) and that this effect was attenuated by CNQX (p > 0.05), a glutamate
AMPA receptor antagonist, and PFT (p > 0.05). B. Examples of neuronal swelling induced by IL-1β in the presence or absence of PFT. Individual neurons
were visualized in situ using a differential interference contrast optical system. C. p21 protein levels were determined in total protein extracts (300 μg)
of mouse corticostriatal slices untreated or treated with IL-1β by Western blot analysis. Each lane represents a different animal and is
composed by a triplicate experiment performed on the same animal. Densitometric analysis of each lane was calculated using Image J software and
data were normalized to actin used as loading control. IL-1β significantly increases the expression of p21 protein. *means p < 0.05.
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flammatory neurodegenerative process of MS patients.
We investigated the possible relationship between the
polymorphism at codon 72 of TP53 gene and the risk of
late progression of neurological disability in subjects with
RRMS, who underwent lumbar puncture to measure
IL-1β levels. Our results indicate that this p53 polymorph-
ism may affect disability progression in MS subjects by
interacting with IL-1β signaling. In line with this, we
found that the Pro/Pro genotype could abrogate the as-
sociation between IL-1β and both clinical andmorphological alterations, measured by disability scores
and OCT parameters, respectively. Retinal alterations in
MS patients accurately model the mechanisms of neuro-
degeneration in MS, and MV and RNFL thickness, ob-
tained by OCT scans, are reliable measures of the integrity
of, respectively, neurons and their axonal projections
within the retina [52,53]. In fact, a close relationship has
been found between RNFL thickness and brain atrophy
evaluated at the MRI in MS subjects [54].
The mechanism underlying the role of Arg72Pro poly-
morphism could be associated with the differential
Table 1 TP53 genotype and genetic model frequency
distribution in the studied subjects
TP53 genotype n (%) IL-1β + IL-1β - p
Arg/Arg 39 (50.6) 53 (57.0)
Arg/Pro 28 (36.4) 29 (31.2)
Pro/Pro 10 (13.0) 11 (11.8) 0.69
Dominant model n (%)
Arg/Arg 39 (50.6) 53 (56.9)
Arg/Pro + Pro/Pro 38 (49.4) 40 (43.1) 0.68
Recessive model n (%)
Arg/Arg + Arg/Pro 67 (87.0) 82 (88.2)
Pro/Pro 10 (13.0) 11 (11.8) 0.81
+, detectable; −, undetectable; n, number.
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three genotypes, as p53 with arginine at codon 72 favors
apoptosis, whereas the Pro encoding allele exhibits a lower
apoptotic potential [31]. In recent years, apoptotic bio-
chemical cascades have been recognized to exert local ac-
tions on the functions and structural dynamics of growth
cones and synapses, to play roles in neuronal plasticity
[55,56]. In particular, active caspases can be detected in
cells that are not destined to die, and it is now widely ac-
cepted that caspases can play non-apoptotic roles in vari-
ous pathological and physiological contexts [57-60].
Studies from several groups collectively point to an essen-
tial function of caspases in synaptic plasticity, independent
of neuronal cell death. Accordingly, two initiator caspases
(caspase-1 and caspase-9) and the effector caspase-3 are
shown to regulate long-lasting synaptic plasticity in hippo-
campal neurons [57,58]. Furthermore, an overexpression
of p73, a protein that shares structural and functional
homology with p53, is sufficient to induce neurite out-
growth [59], but more direct roles for p53 family members
in regulating neurite outgrowth and synaptic modification
have not been established before.
Emerging evidence indicates that apoptotic pathways
are active in early stages of classical neurodegenerative
diseases, such as Alzheimer disease [60] and inflammatoryTable 2 p values for p53 gene/IL-1β interaction effects
TP53 genotype dominant model recessive model
PI 0.002 0.73 0.01
MSSS 0.02 0.30 0.02
MV 0.04 0.16 0.03
RNFL thickness 0.01 0.02 0.005
PI, progression index; MSSS, Multiple Sclerosis Severity Scale; MV, macular
volume; RNFL, retinal nerve fiber layer. Although our sample was too small to
test other statistical associations, higher values of both PI and MSSS were
present in Arg/Arg carriers among patients with undetectable IL-1β (PI: Pro/Pro
0.16 +/− 0.13, Arg/Pro 0.14 +/− 0.09, Arg/Arg 0.21 +/− 0.17; MSSS: Pro/Pro 1.73
+/− 1.62, Arg/Pro 1.73 +/− 1.68, Arg/Arg 2.61 +/− 2.33).neurodegenerative diseases as MS (present work). The
apoptotic cascade could mediate synapse dysfunction and
loss, before the advent of cell death and neurodegenera-
tion. These new insights have potential implications for
neuroprotection, and highlight the regulatory role of p53
in the excitatory synaptic transmission under both normal
and pathological conditions.
When immune challenge becomes chronic and/or un-
regulated, as in MS, the CNS can be chronically exposed
to cytokines with resultant neuronal and axonal dysfunc-
tions, later irreversible cellular damage and sustained
neurological disability. Consistently, persistent presence
of IL-1β has been associated with disability progression
in RRMS [16].
Inflammatory cytokines can lead to neuronal death by
driving excitotoxicity and/or activating apoptotic path-
ways, as our present data seem to indicate. However,
IL-1β could not be the only significant factor to explain
disability or poor prognosis in RRMS.
A limitation of this study was the small sample size.
Further studies on larger samples of patients are war-
ranted to replicate these data and to assess the effect of
p53 per se on disability progression in MS. P53, in fact,
could affect different pathways of apoptosis induction,
thus leading to neurodegenerative damage in MS. In line
with this, higher progression indexes were evident among
carriers of the allele with higher apoptotic potential, re-
gardless the presence of IL-1β. Nonetheless, our study
provides compelling evidence of the synaptic mechanism
linking cytokine signaling and excitotoxic neurodegenera-
tion in MS, and suggest that targeting IL-1β-p53 effects
on synaptic transmission might be neuroprotective in this
severe disease.Methods
This study complied with the principles of the Declar-
ation of Helsinki, and was approved by the Ethical
Committee of the Policlinico Università Tor Vergata in
Rome. All the subjects gave their written informed con-
sent to the study. In regard to animal experiments, all
efforts were made to minimize animal suffering and to re-
duce the number of mice used, in accordance with the
European Communities Council Directive of November 24,
1986 (86/609/EEC).In vitro neurophysiology and cell swelling experiments
Female C57BL/6 mice were used for all the experiments.
Six- to eight-week-old mice were killed by cervical dis-
location under halothane anesthesia, and corticostriatal
coronal slices (200 μm) were prepared from fresh tissue
blocks of the brain using a vibratome [4,7] A single slice
was transferred to a recording chamber and submerged in
a continuously flowing artificial CSF (aCSF) (34°C, 2–3
Table 3 Demographic and clinical characteristics of MS
subjects, according to CSF contents of IL-1β
IL-1β
Total + - p
Number 170 77 93
Gender (M/F) 62/108 27/50 35/58 0.75
Age (years) 36.3 ± 9.5 37.3 ± 10.1 35.1 ± 8.8 0.12
Disease duration (years) 10.5 ± 5.3 10.8 ± 5.9 10.1 ± 4.8 0.42
EDSS 2.2 ± 1.7 2.8 ± 1.9 1.7 ± 1.4 <0.01
+, detectable; −, undetectable; M, male; F, female; EDSS, Expanded Disability
Status Scale.
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of the control aCSF was (in mM): 126 NaCl, 2.5
KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 11 glucose,
25 NaHCO3. Whole cell patch clamp recordings were
made in voltage clamp mode [4,7], at the holding potential
of −80 mV to study spontaneous glutamate-mediated
sEPSCs. Drugs were applied by dissolving them to the de-
sired final concentration in the bathing aCSF. One to 6
cells per animal were recorded. For each type of experi-
ment, at least 4 distinct animals were employed. Through-
out the text, ‘n’ refers to the number of cells, unless
otherwise specified. To measure cell swelling [4], a base-
line image of the cells was obtained and stored. The slice
was then exposed to the investigated cytokine for the
entire duration of the experiment. Individual neurons
were visualized in situ using a differential interference
contrast (Nomarski) optical system. This employed a 40×
water immersion objective combined with an infrared fil-
ter, a monochrome charge-coupled device camera (COHU
4912; Cohu Electronics, Poway, CA), and a PC-compatible
system for analysis of images and contrast enhancement
(Winvision 2000; Delta Sistemi, Rosolina, Italy). Digital
images were stored for subsequent analysis. Cells were
typically visualized from 10 to 150 μm below the surface
of the slice. To quantify changes in response to inflamma-
tory cytokines, in the presence or in the absence of CNQX
and PFT, cross-sectional somatic area was measured (IAS,
Delta Sistemi). Each measurement was made 2 or 3 on in-
dividual medium-sized striatal neurons, and the average
value was recorded at each time point. Drugs were applied
by dissolving them to the desired final concentration in
the bathing ACSF. Drugs were: bicuculline (10 μM), PFT
(30 μM), PMA (2 μM)(from Sigma-RBI, St. Louis, USA);
chelerythrine (10 μM) (from Alomone Labs); capsaicin
(10nM), capsazepine (10 μM), CNQX (10 μM) (from
Tocris Cookson, Bristol, UK), IL-1β (30 ng/ml), IL-1 re-
ceptor antagonist (IL-1ra; 10 μg/ml) (from R&D Systems,
Minneapolis, USA); nutlin-3 (10 μM) (from Calbiochem,
San Diego, USA), TNF-α (600 nM) (from Peprotech,
Rocky Hill, USA). The purity of all the drugs used for the
experiments was at least ≥95%, as reported in the manu-
facturer’s catalogue.
Western blot analysis
Mouse corticostriatal slices of C57BL/6 J females were
frozen after 2 h of incubation with medium or IL-1β
30 ng/ml. Tissues were transferred in microcentrifuge
tubes containing RIPA buffer [50 mMTris-HCl pH 8,
200 mMNaCl, 2 mM EDTA, 1% NP-40, 0.5% sodium
deoxycholate, 0.05% SDS, 1 mM Na3VO4, 1 mg/ml leu-
petin, 1 mg/ml aprotinin, 5 mM NaF, 1 mM PMSF
freshly added] and homogenized using a pestle mounted
in a motorized chuck. Homogenized tissues were left on
ice for 15 mins, cell lysates were centrifuged for 15 minsat 15000 g at 4°C, and the supernatants were collected
and used for Western blot analyses. Cell extracts were
diluted in Laemmli buffer and boiled for 5 mins at 95°C.
Proteins were separated on 12% SDS-PAGE gels and
transferred to nitrocellulose (NC) membranes (What-
man, Sigma-Aldrich, GE Healthcare Life Science) using
a wet blotting apparatus (Amersham Biosciences). Mem-
branes were saturated for 1 h at room temperature with
5% non-fat dry milk in phosphate-buffered saline (PBS),
containing 0.1% Tween-20. Membranes were incubated
with the following antibodies overnight at 4°C: rabbit
polyclonal anti-rat p21 (Santa Cruz Biotechnology; 1:500
dilution in 3% non-fat dry milk in PBS, containing 0.1%
Tween-20), mouse monoclonal anti-rat β-actin (Sigma-
Aldrich; 1:5000 dilution in 5% non-fat dry milk in PBS,
containing 0.1% Tween-20). Secondary anti-rabbit or
anti-mouse IgGs conjugated to horseradish peroxidase
(Cell signaling) were incubated with the membranes for
1 h at room temperature at a 1:2000 dilution in PBS con-
taining 0.1% Tween 20. Immunostained bands were de-
tected by chemiluminescent method (Pierce ECL Western
Blotting Substrate, Thermo Scientific).MS subjects and CSF withdrawal
Demographical features and clinical characteristics of
RRMS patients are shown in Table 3. The minimum and
maximum last EDSS values were respectively 0 and 6.5. All
patients had received immunomodulatory treatment dur-
ing the course of their disease. First-line treatment was
started for all patients at the time of the diagnosis. All pa-
tients matched published criteria for the diagnosis of
RRMS [61]. All were in clinical and radiological remission
phase of the disease and naïve to any disease modifying
treatment at the time of CSF withdrawal. In particular, sub-
jects who experienced a clinical relapse within 60 days or
showed any gadolinium (Gd)-enhanced lesions at brain
magnetic resonance imaging (MRI) were excluded, as re-
ported [16]. Enrolled subjects reported no previous history
of chronic inflammatory diseases, or signs of local or sys-
temic infection at the time of CSF collection. Lumbar
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Blood sample collection, CSF withdrawal and clinical
assessments were performed at the MS Center of the Tor
Vergata University Hospital of Rome by MS specialist
neurologists. Demographic and clinical information
were derived from medical records. MS disease onset
was defined as the first episode of focal neurological
dysfunction indicative of MS. Disease duration was esti-
mated as the number of years from onset to the last as-
sessment of disability. At the time of confirmed
diagnosis, all MS patients had started first-line disease-
modifying therapies, without differences comparing
between patients with undetectable and detectable CSF
levels of IL-1β (IL-1β+: daily glatiramer acetate 20 mg s.c.
n = 28/77, interferon beta 1a 44 mcg s.c. three times
weekly n = 34/77, interferon beta 1a 30 mcg i.m. n = 5/77,
or interferon beta 1b 250 mcg s.c. every other day
n = 10/77; IL-1β-: glatiramer acetate n = 35/93, interferon
beta 1a 44 mcg n = 39/93, interferon beta 1a 30 mcg
n = 6/93, interferon beta 1b n = 13/93).
IL-1β determination
To determine IL-1β, the CSF was centrifuged and im-
mediately stored at −80°C until analyzed using Bio-Plex
Multiplex Cytokine Assay (Bio-Rad Laboratories, Hercules,
CA), according to manufacturer’s instructions. Concentra-
tions of IL-1β were calculated according to a standard
curve and expressed as picograms per milliliter. When the
concentrations of the cytokine were below the detection
threshold, they were assumed to be 0 pg/ml [16].
Disability assessment
Disability was determined by a specially trained (Neu-
rostatus, 2006. Available at http://www.neurostatus.net)
and certified examining neurologist using Expanded
Disability Status Scale (EDSS), a 10-point disease sever-
ity score derived from nine ratings for individual neuro-
logical domains [62]. The EDSS, evaluated every six
months since diagnosis, was used in combination with
disease duration to calculate two measures of disease
severity, the PI and the MSSS. PI was defined as EDSS/
disease duration. The MSSS is an algorithm that relates
EDSS scores to distribution of disability in patients with
comparable disease durations [63]. EDSS scores were
taken in account for the assessment of disability progression
when obtained at least 30 days since stabilization/resolution
of previous relapse and/or corticosteroid treatment. Only
patients with at least four years of follow-up were included.
Optical coherence tomography
Medical history with respect to visual symptoms was
taken from all MS subjects. Self-report and physician re-
port were confirmed by record review. A subset of RR
MS patients (n = 118) without history of optic neuritisand ophthalmological disease underwent measurement
of RNFL thickness and MV for both eyes using Stratus
OCT™; software version 4.0.2, Carl Zeiss Meditec, Inc.)
[64]. Briefly, for MV, retinal thickness was measured
automatically as the distance between the vitreoretinal
interface and the anterior boundary of the retinal pig-
ment epithelium. Stratus OCT images were generated
using the fast map scan protocol consisting of six radial
scans spaced 30° apart, with each scan measuring 6 mm
in length. Each image had a resolution of 10 μm axially
and 20 μm transversally. All Stratus OCT images had a
signal strength of 6 μm. RNFL thickness measurements
were read from the automated measurements generated
by the machine using the Fast RNFL analysis. For the
study scanning was performed after pharmacological
dilation. Average RNFL thickness for 360° around the
optic disc was recorded. Values were adjusted for age.
One randomly chosen eye from each subject was in-
cluded in the study. Testing was performed by trained
technicians experienced in examination of patients for
research studies, and patients wore their habitual glasses
or contact lenses for distance correction.
Genotyping
Genomic DNA was extracted from peripheral blood
lymphocytes of patients. Genotyping was performed
using MassARRAY high-throughput DNA analysis
with Matrix-assisted laser desorption/ionization time-
of-flight (MALDI-TOF) mass spectrometry (Sequenom,
Inc., San Diego, CA). SNP (G-to-C transversion) at codon
72 (rs1042522) of the gene encoding p53 (TP53) was
genotyped using iPLEX Gold technology following manu-
facturer protocol (Sequenom). Detailed description of
methods has been previously reported [65].
Statistical analysis
For electrophysiological data, statistical analysis was per-
formed using a paired or unpaired Student’s t-test if com-
parisons were between two groups. Multiple comparisons
were analyzed by one-way ANOVA for independent and/or
repeated measures followed by Tukey HSD. MS subjects
were divided into two groups according to the detectable
(+ group) or undetectable (− group) CSF levels of IL-1β.
Differences among groups were compared by univariate
analysis using Student’s t test or Mann–Whitney test for
continuous variables and Fisher Exact Test or Chi-
square Test for categorical variables.
Patient characteristics according to CSF IL-1β con-
tents were shown in Table 3. The 3 (genotypes) × 2
(cytokine detection) between subjects analysis of covari-
ance, was performed to investigate the interaction effects
between CSF IL-1β and TP53 genotype, with disease
duration as covariate for ophthalmologic parameters.
The 2 (genetic model) × 2 (cytokine detection) between
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covariate, was performed to evaluate the effects of CSF
IL-1β on dominant (Arg/Arg vs. Arg/Pro + Pro/Pro) and
recessive (Arg/ Arg + Arg/Pro vs. Pro/Pro) models. The
3 × 2 and 2 × 2 ANOVAs were replicated for disability
progression indexes.
Electrophysiological data were presented as the
mean ± standard error (SE). Other data were presented
as mean ± standard deviation (SD). A p-value (p) of
less than 0.05 was considered statistically significant.
The threshold for significance applied throughout of
the present study was not taking into account the
number of comparisons performed.
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